Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824963 | 0.88 | ALDH1A1 (0.43) | NPC1RAB9AATMALDH1A1L3MBTL1 | |
| SCHEMBL1827397 | 0.88 | STIM1 (0.39) | NPC1RAB9ATRPV1ABL1MAPT | |
| SCHEMBL1827911 | 0.87 | IL2 (0.44) | NPC1RAB9AATMALDH1A1L3MBTL1 | |
| SCHEMBL2786877 | 0.85 | HTT (0.38) | NPC1RAB9ATRPV1ABL1MAPT | |
| SCHEMBL1829406 | 0.81 | ALDH1A1 (0.41) | NPC1RAB9AATMALDH1A1L3MBTL1 | |
| SCHEMBL1830426 | 0.81 | TRPV1 (0.39) | NPC1RAB9AL3MBTL1PTPN1TRPV1 | |
| SCHEMBL1826590 | 0.80 | NPC1 (0.40) | NPC1RAB9AATMALDH1A1PTPN1 | |
| SCHEMBL1824137 | 0.80 | RAB9A (0.40) | NPC1RAB9ATRPV1ABL1MAPT | |
| SCHEMBL12988289 | 0.79 | IL2 (0.43) | RAB9A | |
| SCHEMBL1828154 | 0.76 | TRPV1 (0.40) | NPC1RAB9ATRPV1ABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651232-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1651232-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1653968-A4 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1653968-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | Synta Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | claimed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | claimed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | disclosed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | NPC1 142/4885RAB9A 1725/4885ATM 2089/4885 |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | ORAI1, CACNA1C, CACNA1F | NPC1 337/4885RAB9A 841/4885ATM 4776/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | NPC1 142/4885RAB9A 1725/4885ATM 2089/4885 |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, PTPN3, FKBP3 | NPC1 405/4885RAB9A 1662/4885ATM 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.